2020 Schedule and Program for the ASH Meeting on Lymphoma Biology
The 2020 ASH Meeting on Lymphoma Biology has been canceled. ASH has decided to cancel the meeting as a precautionary measure in response to the COVID-19 outbreak in the U.S. and worldwide. The health and safety of our meeting attendees is ASH’s top priority.
ASH encourages those who had planned to submit abstracts for this meeting to instead submit for consideration to ASH’s Annual Meeting and Exposition, the premier event in malignant and non-malignant hematology. The abstract submission site will open on June 4, 2020.
ASH encourages those who had planned to submit abstracts for this meeting to instead submit for consideration to ASH’s Annual Meeting and Exposition, the premier event in malignant and non-malignant hematology. The abstract submission site will open on June 4, 2020.
The following program is preliminary and subject to change.
-
Thursday - August 6
2:00 p.m. - 7:00 p.m. Registration 5:00 p.m. – 5:15 p.m. Welcome, Introduction, and Announcements 5:15 p.m. – 6:00 p.m. Opening Keynote Address
Chair: Ralf Küppers, PhD
Riccardo Dalla-Favera, MD
The Making of Diffuse Large B-Cell Lymphoma6:00 p.m. – 7:00 p.m. Welcome Reception and Exhibits Open -
Friday - August 7
7:00 a.m. – 9:15 p.m. Registration 7:00 a.m. – 8:00 a.m. Breakfast and Exhibits Open 8:00 a.m. – 10:00 a.m. Session 1: Germinal Center Biology
Chair:
Bertrand Nadel, PhD
Speakers:
Klaus Rajewsky, MD
Control of the Competitive Fitness of MYC-driven B Lymphoma Cells
Dinis Calado, PhD
Differentiation Processes of Germinal Center B Cells and Lymphomagenesis
Jagan R. Muppidi, MD, PhD
Evasion of Cell Death in Germinal Center-Derived Lymphomas
Oral Abstract Talk 1
Oral Abstract Talk 210:00 a.m. – 11:15 a.m. Session 2, Part 1: Novel Genetic and Epigenetic Mechanisms in Lymphomagenesis
Chair:
Dan A. Landau, MD, PhD
Speakers:
Ari Melnick, MD
Precision Epigenetic Therapy for Follicular and Diffuse Large B cell Lymphoma
Hans-Guido Wendel, MD
Exploring the Link between Serine Metabolism and Lymphoma Epigenetics
Oral Abstract Talk 311:15 a.m. – 11:30 a.m. Break 11:30 a.m. – 12:45 p.m. Session 2, Part 2: Novel Genetic and Epigenetic Mechanisms in Lymphomagenesis
Chair:
Dan A. Landau, MD, PhD
Speakers:
Jude Fitzgibbon, PhD
Targeting KMT2D Mutations in Follicular Lymphomas
Dan A. Landau, MD, PhD
The Epigenetic Evolution of Cancer Cells
Oral Abstract Talk 412:45 p.m. – 1:45 p.m. Lunch and Exhibits 1:45 p.m. – 3:45 p.m. Continuing Conversations 3:45 p.m. – 5:15 p.m. Poster Presentations 5:15 p.m. – 6:30 p.m. Session 3, Part 1: Disrupted Signaling Pathways and Microenvironment in Lymphoma
Chair:
Christian Steidl, MD
Speakers:
Margot Thome-Miazza, PhD
Novel Insights into the Role of the CBM Complex in Lymphoma
Karin Tarte, PharmD, PhD
Pro-Tumoral Microenvironment in Follicular Lymphoma: Heterogeneity and Function
Oral Abstract Talk 56:30 p.m. – 8:00 p.m. Dinner 8:00 p.m. – 9:15 p.m. Session 3, Part 2: Disrupted Signaling Pathways and Microenvironment in Lymphoma
Chair:
Christian Steidl, MD
Speakers:
Margaret A. Shipp, MD
Deregulated Signaling Pathways in Large B Cell Lymphomas
Martina Seiffert, PhD
Myeloid-Derived Suppression and T-cell Exhaustion in the Microenvironment of Chronic Lymphocytic Leukemia
Oral Abstract Talk 6 -
Saturday - August 8
7:00 a.m. - 8:45 p.m. Registration 7:00 a.m. – 8:00 a.m. Breakfast and Exhibits Open 8:00 a.m. – 10:20 a.m. Session 4: Understanding Mechanisms of Sensitivity and Resistance to Novel Therapies in Lymphoma
Chair:
Ari Melnick, MD
Speakers:
Ash A. Alizadeh, MD, PhD
Disease Monitoring and Outcome Prediction for B cell Lymphomas Using Circulating Tumor DNA
Louis Staudt, MD, PhD
Overcoming Resistance to Targeted Therapy of Lymphoma using Multi-drug Combinations
Anas Younes, MD
Biomarker-Driven Trials in the Era of Combination Therapy
Oral Abstract Talk 7
Oral Abstract Talk 8
Panel Discussion with Invited Speakers10:15 a.m. - 10:35 a.m. Break 10:35 a.m. – 12:35 p.m. Session 5: NK/T-cell Lymphomas
Chair:
Wing “John” C. Chan, MD
Speakers:
Seishi Ogawa, MD, PhD
Molecular Genetics of Peripheral T-cell Lymphomas
Teresa Palomero, PhD
Role and Mechanisms of VAV1 Translocations in PTCL
Kojo S. J. Elenitoba-Johnson, MD
Novel Insights in the Role of Ubiquitin Ligases in T-cell Function and Neoplasia
Oral Abstract Talk 9
Oral Abstract Talk 1012:35 p.m. - 1:45 p.m. Lunch and Exhibits 1:45 p.m. – 3:45 p.m. Session 6: Germinal Center-Derived Lymphomas
Chair:
Laura Pasqualucci, MD
Speakers:
Sandrine Roulland, PhD
Novel Insights into the Natural History of Follicular Lymphoma Progression
Reiner Siebert, PhD
New Insights in the Pathogenesis of Burkitt Lymphoma
Christian Steidl, MD
Pathogenic Crossroads in Primary Mediastinal B cell Lymphomas and Hodgkin Lymphoma
Oral Abstract Talk 11
Oral Abstract Talk 123:45 p.m. – 5:15 p.m. Poster Presentations 5:15 p.m. – 6:45 p.m. Dinner 6:45 p.m. – 8:45 p.m. Session 7: Chronic Lymphocytic Leukemia and other Small B cell Neoplasms
Chair:
Elias Campo, MD, PhD
Speakers:
Davide Rossi, MD, PhD
Genomic Complexity in Splenic Marginal Zone Lymphoma
Catherine Wu, MD
Tumor Dynamics in the Evolution of Chronic Lymphocytic Leukemia
Iñaki Martin Subero, PhD
Epigenetic Dysregulation in Small B cell Lymphoid Neoplasms
Oral Abstract Talk 13
Oral Abstract Talk 14 -
Sunday - August 9
7:00 a.m. – 1:35 p.m. Registration 7:00 a.m. – 8:00 a.m. Breakfast, Exhibits, and Steering Committee Meeting 8:00 a.m. – 9:15 a.m. Session 8, Part 1: Immunotherapies of Lymphomas
Chair:
Margaret A. Shipp, MD
Speakers:
Stephen Ansell, MD, PhD
Alternative Checkpoints in Lymphoma
Catherine M Bollard, MD
Overcoming TGFb in the Tumor Microenvironment with Cell Therapy
Oral Abstract Talk 159:15 a.m. – 10:50 a.m. Session 8, Part 2: Immunotherapies of Lymphomas
Chair:
Margaret A. Shipp, MD
Speakers:
Ranjana Advani, MD
Targeting CD47 for Lymphoma Therapy
Ronald Levy, MD
In Situ Vaccination for the Therapy of Lymphoma
Oral Abstract Talk 16
Panel Discussion with Invited Speakers10:45 a.m. – 11:05 a.m. Break 11:05 a.m. – 1:05 p.m. Session 9: Late-Breaking Scientific Session
Invited Speaker 28
Invited Speaker 29
Invited Speaker 30
Oral Abstract Talk 17
Oral Abstract Talk 181:05 p.m. – 1:35 p.m. Closing Remarks 1:35 p.m. Departures